Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128020 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAOPRM1OPRD1CHRM3 | |
| SCHEMBL8817476 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAOPRM1OPRD1KCNA5 | |
| SCHEMBL7592805 | 0.84 | CHRM3 (0.57) | SMN1; SMN2CHRM3GAA | |
| SCHEMBL2127676 | 0.83 | CYP2B6 (0.59) | CHRM3 | |
| SCHEMBL2126740 | 0.83 | CYP2B6 (0.59) | CHRM3 | |
| SCHEMBL3043721 | 0.83 | CYP2B6 (0.59) | CHRM3 | |
| SCHEMBL4444477 | 0.83 | CYP2B6 (0.59) | CHRM3 | |
| SCHEMBL26698239 | 0.81 | CHRM3 (0.55) | OPRM1CHRM3ALDH1A1TSHRKMT2A | |
| SCHEMBL18284663 | 0.80 | SIGMAR1 (0.45) | SMN1; SMN2OPRD1CHRM3CYP3A4ALDH1A1 | |
| SCHEMBL27772009 | 0.80 | CHRM3 (0.57) | SMN1; SMN2CHRM3HIF1AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| CN-101610813-A | Quinuclidinol derivatives as muscarinic receptor antagonist | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | SMN1; SMN2 4582/4885LMNA 2742/4885OPRM1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.